(HealthDay News) — A new type of whole-body magnetic resonance imaging (MRI) may allow detection and staging of tumors in children and young adults, without exposure to ionizing radiation, according to research published online February 19 in The Lancet Oncology.

Christopher Klenk, MD, of Stanford University in California, and colleagues performed whole-body diffusion-weighted MRI scans, using the iron supplement ferumoxytol as a contrast agent, and standard clinical 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) scans. Participants included 22 children and young adults with malignant lymphomas and sarcomas.

The researchers found that, compared with zero exposure to radiation for the whole-body MRI scans, exposure to ionizing radiation from the PET/CT scans averaged 12.5 mSv. For whole-body diffusion-weighted MRI scans, compared with PET/CT scans, sensitivity was 90.8 vs.93.7%, specificity was 99.5 vs 97.7%, and diagnostic accuracy was 98.3 vs.97.2%. Tumor staging results showed good agreement between the two imaging modalities.

“Although the technical feasibility and potential diagnostic value of using ultrasmall superparamagnetic iron oxide particles in a whole-body diffusion-weighted MRI protocol has been shown in these patients, further work is needed before it can become a clinical alternative to 18F-FDG-PET/CT,” writes the author of an accompanying editorial.

One author disclosed financial ties to the biomedical industry.

Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)